Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kinda crazy how much Hans been struggling with MEDH status for 4 years now.
Ticker needs to be current soon to anticipate schedule change of cannabis from 1 to 3
Attorney added to the roster? Addition to personnel?
https://www.linkedin.com/in/kate-demitrus
Italian Physician calling for Metformin therapy for AMD! Watch video
https://www.healio.com/news/ophthalmology/20231212/video-metformin-may-have-beneficial-effect-on-amd-progression
https://titanpartnersgrp.com/transactions
Paul Michaels liked this recent transaction by this capital group. He is being very active on LinkedIn
Accurate!
Load up! Fun
Plenty of money to buy CUBT out in the future. Just need FDA IND Approval, Complete Phase 1/2 trial…. And Sold! >$1
$0.02 will not last. Eyes towards a Nickel!
Probably get there before any material event on speculation alone!!!
$0.15 to $0.40 on filing FDA IND application with approval for Phase 1/2 start.
>$1.50 for completion of Phase1/2 trial down the road and positive outcomes…. I bet they sell it here at the sold called inflection point.
Load them shares up know! Future FDA news could bring on massive new eyes imo
$0.02’s won’t last. Strength built at $0.03’s and this ends at a Nickel until a new wave of interest come!
Everything under $0.03 right now is lovely. Just add when we can for us small guys.
A whale will come chomping at these shares in due time…
Doubt Hans gets it squared away by Jan 10th. However I do believe the intent is truthful.
Unsure how many locations there are. Website reflects 4. It looks achievable to scale to 20 locations going at it alone.
Staff is cannabis users so of course a bit “lazy”lol. If not then let them prove they’re actually working their ass off.
Do you believe you? LOL
$0.03 by years end?
Which one of you whales want to just give us all a huge dopamine release!!!
Someone adding …smartly
Building their position
Expert market.
2024 could be a lucky year if MEDH would only be preparing to be current and back to trading.
Need Integrity and Accountability from CEO
Website updated. When current? When DAZE? …. When Rockets? When Lambo?
https://www.lazydazeshop.com/
Get current. And get financially organized.
Hans blogged on MEDH still in it.
https://www.linkedin.com/posts/hansenriquez_history-of-medical-marijuana-in-texas-activity-6900040910323671040-KhiN
Unlikely.
Unlikely.
Boots on the ground you say?
I see what you did there lol.
Wild speculation
Start of Phase 1: $0.16
Start of Phase 2: $0.45
Start of Phase 3: $1.98
Per CUBT website they desire to take it to “Completion of Phase I / II Trial”. Looking like that would take it to a market cap of $250 million to $1.25 billion. Wide range. Hopefully a Japanese partner or buyer.
2024, 2025, 2026 ? When?
$0.03 soon
Seems like a possibility to begin taking position for some new blood.
Garr would help with a CEO Blog to just show their presence.
https://www.linkedin.com/in/paul-m-michaels
Paul’s LinkedIn activity is interesting. Japan Startups, Spartan Capital, Lucosky Brookman…
What you up to Pablo?
Disclosures
The University of Chicago Institute for Translational Medicine and the Bucksbaum Institute for Clinical Excellence funded the research.
Skondra reported receiving consulting fees from Biogen, LaGrippe Research, Focuscope, AbbVie, Alimera Science, Trinity Life Sciences, Keywest Health, and Lumina. A co-author reported receiving personal fees from Alimera Sciences, Iveric Bio, Apellis Pharmaceuticals, Coherus BioSciences, EyePoint Pharmaceuticals, AbbVie, Biogen, and Regeneron.
Domalpally had no disclosures.
Primary Source
JAMA Ophthalmology
Source Reference: opens in a new tab or windowAggarwal S, et al "Metformin use and age-related macular degeneration in patients without diabetes" JAMA Ophthalmol 2023; DOI: 10.1001/jamaophthalmol.2023.5478.
Compared with no metformin use, 2-year cumulative doses of 1 to 270 g and 271 to 600 g were linked to 18% and 14% lower odds of dry AMD development.
The findings from this study are "very encouraging" and provide support for launching a randomized trial, Skondra told MedPage Today.
Need Hans to develop this into a real accountable public Co.
Reviews for Albuquerque coming in 5 stars
Would be like us running to $0.40
Does Richard Garr even want to recover reputation from Neuralstem failures or is he really wanting to ruin two companies… I don’t think so…
But his silence and lack of rapport with shareholders creates that sinister feeling to it
Need a CEO to be CEO right about now!
Would be so nice to see an accountable public company grow in 2024… lots of fun to be squared away and invite new inevestors
I see that Hans isn’t quitting… ever
Richard and Paul should provide a soft update (possibly ceo blog or update investor presentation) to highlight any pivot from Macular Degeneration to Glaucoma interest.
If the pivot I speculate is correct then this is more promising as the data is relevant for a significant outcome with glaucoma imo.